The Polypharmacy Challenge in Tardive Dyskinesia

By Gina ShawFor decades, tardive dyskinesia (TD) was most closely associated with long-term treatment of schizophrenia with first-generation antipsychotics. But as dopamine-blocking medications have spread across multiple specialties and indications, clinicians increasingly encounter TD in patients with complex medication regimens and diagnoses far beyond psychotic disorders (Tremor Other Hyperkinet Mov [N Y] 2013;3:tre-03-161-4138-1; Epidemiol Psychiatr Sci 2021;30:e28).figure { display:inline-